Inari Medical Inc
NASDAQ:NARI
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.11
65.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Inari Medical Inc
Inari Medical Inc
Cost of Revenue
Inari Medical Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inari Medical Inc
NASDAQ:NARI
|
Cost of Revenue
-$59.1m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-115%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Cost of Revenue
-$11B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$4.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$7.9B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$2.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-14%
|
|
Inari Medical Inc
Glance View
Inari Medical Inc., nestled in the heart of Irvine, California, embarked on a mission to revolutionize the treatment for venous diseases with a sense of urgency and ingenuity. Founded in 2011, this medical device company has become a beacon of innovation in the healthcare sector, relentlessly focused on addressing the unmet needs in the treatment of venous thromboembolism (VTE) conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These life-threatening conditions impact millions globally, presenting a critical challenge that Inari aims to tackle head-on. Their pioneering spirit is showcased in their flagship devices—the FlowTriever and ClotTriever—designed to remove large clots with less risk compared to traditional, invasive surgical methods. By providing minimally invasive mechanical thrombectomy devices, Inari Medical has streamlined treatments to improve patient outcomes, ultimately reducing the burden on healthcare systems. Revenue streams at Inari are intrinsically tied to their innovative products, which are integral in modern therapeutic strategies for clot removal. The commercial success of FlowTriever and ClotTriever is driven by their effectiveness and safety profile, appealing to hospitals and medical professionals looking for advanced solutions to treat VTE. Inari's business model thrives on the sales and adoption of these devices, supported by robust clinical evidence that underpins their efficacy. With a blend of aggressive research and development, education programs for physicians, and a strategic global market expansion, Inari Medical is poised to continue growing in the med-tech sector. Their commitment to addressing large medical needs with cutting-edge solutions not only defines their financial blueprint but also underscores their dedication to transforming patient care across the globe.
See Also
What is Inari Medical Inc's Cost of Revenue?
Cost of Revenue
-59.1m
USD
Based on the financial report for Dec 31, 2023, Inari Medical Inc's Cost of Revenue amounts to -59.1m USD.
What is Inari Medical Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-115%
Over the last year, the Cost of Revenue growth was -33%. The average annual Cost of Revenue growth rates for Inari Medical Inc have been -66% over the past three years , -115% over the past five years .
You don't have any saved screeners yet
